Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Hikma Pharmaceuticals ( (GB:HIK) ) has provided an update.
Hikma Pharmaceuticals announced a transaction involving the disposal of shares by a Person Discharging Managerial Responsibilities (PDMR), Susan Ringdal. The transaction involved the sale of 3,300 ordinary shares at a price of £19.47 each, totaling £64,251, conducted on the London Stock Exchange. This disclosure is in compliance with the EU Market Abuse Regulation, signaling transparency in the company’s managerial transactions, which is crucial for maintaining stakeholder trust.
More about Hikma Pharmaceuticals
Hikma Pharmaceuticals is a multinational pharmaceutical company based in London, primarily focusing on manufacturing and marketing branded and non-branded generic medicines. The company operates across various markets, providing essential pharmaceuticals to healthcare providers and patients.
YTD Price Performance: 12.63%
Average Trading Volume: 443,394
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: £4.33B
See more insights into HIK stock on TipRanks’ Stock Analysis page.
